Residency · Residency · General Surgery
Management of the Hostile Abdomen and Enterocutaneous Fistula
Introduction
The hostile abdomen, also known as the frozen abdomen or obliterated peritoneal cavity, presents one of the most challenging clinical scenarios in general surgery. Defined by dense intra-abdominal adhesions, loss of domain, prior mesh, and distorted anatomy, it frequently leads to enterocutaneous fistula (ECF) formation. ECFs carry significant morbidity and mortality, with rates of 6 to 33% depending on complexity. A systematic, multidisciplinary approach emphasizing patient optimization before definitive surgery is essential for successful outcomes.
Definition and Etiology of the Hostile Abdomen
A hostile abdomen is a peritoneal cavity rendered difficult or dangerous to enter and operate in due to multiple prior surgeries, adhesions, mesh, radiation, infection, or open abdomen management. Common antecedents include multiple prior laparotomies (each additional operation increases adhesion severity), previous damage control surgery with open abdomen management, prior mesh placement (particularly intraperitoneal synthetic mesh), abdominal radiation therapy, prior peritonitis or intra-abdominal sepsis, inflammatory bowel disease (especially Crohn's disease), and enterocutaneous fistula with surrounding inflammation.
Enterocutaneous Fistula: Classification and Pathophysiology
Classification
| Output Classification | Volume | Typical Source | Spontaneous Closure Rate |
|---|---|---|---|
| High | >500 mL/day | Proximal small bowel | Low |
| Moderate | 200–500 mL/day | Distal small bowel | Moderate |
| Low | <200 mL/day | Colon | High |
ECFs are classified by anatomy (esophageal, gastric, duodenal, jejunal, ileal, colonic, or rectal), by output, and by complexity. High-output fistulae produce more than 500 mL per day, are typically from the proximal small bowel, and are associated with severe metabolic derangements, malnutrition, and skin breakdown. Moderate-output fistulae produce 200 to 500 mL per day. Low-output fistulae produce less than 200 mL per day, are typically colonic, and are more likely to close spontaneously. In terms of complexity, simple (Type 1) fistulae are single with a short tract under 2 cm, no associated abscess, and no organ involvement. Complex (Type 2) fistulae involve multiple fistulae, long or branching tracts, associated abscesses, opening into the base of a wound, associated bowel discontinuity, or involvement of other organs such as enterovesical or enterovaginal communications.
Etiology
Postoperative causes account for 75 to 85% of ECFs and include anastomotic leak, inadvertent enterotomy, ischemia, and missed bowel injury. Spontaneous causes account for 15 to 25% and include Crohn's disease, radiation enteritis, malignancy, diverticular disease, and foreign body such as mesh erosion. The mnemonic FRIENDS identifies factors preventing spontaneous closure: Foreign body, Radiation, Infection/IBD, Epithelialization of the tract, Neoplasm, Distal obstruction, and Short fistula tract (under 2 cm) or high output (over 500 mL/day).
<image>Anatomical diagram showing types of enterocutaneous fistula classified by location (proximal jejunal high-output, distal ileal moderate-output, and colonic low-output), with a cross-sectional view of a fistula tract showing epithelialization, associated abscess cavity, and the relationship between tract length and likelihood of spontaneous closure</image>
Initial Management: Sepsis Control and Resuscitation
The SNAP Protocol (Sepsis, Nutrition, Anatomy, Procedure)
The first phase focuses on sepsis control and stabilization during the initial 1 to 2 weeks. Source control is achieved through CT-guided percutaneous drainage of abscesses, avoiding reoperation in the acute setting whenever possible to prevent entering a hostile abdomen. Wound management establishes controlled fistula output and protects the surrounding skin from effluent. Fluid and electrolyte resuscitation is critical because high-output fistulae cause massive losses of sodium, chloride, bicarbonate, potassium, and water that require meticulous replacement. Broad-spectrum antibiotics are administered as indicated, with source control taking priority.
Fluid and Electrolyte Management
Proximal small bowel fistulae lose fluid rich in sodium (approximately 140 mEq/L), chloride, and bicarbonate, requiring replacement with isotonic saline and bicarbonate supplementation. Distal small bowel and colonic fistulae lose potassium-rich fluid. Output reduction strategies include proton pump inhibitors to reduce gastric acid secretion, which is a major contributor to fistula output. Octreotide, a somatostatin analogue, reduces GI secretions and is useful for output reduction, though evidence for accelerating fistula closure is conflicting. Loperamide and codeine slow transit and reduce output. Oral rehydration solutions exploit sodium-glucose cotransport for active absorption and are more effective than water or hypotonic fluids.
Wound and Skin Management
Effluent contact with skin causes severe irritant dermatitis, pain, and further wound breakdown. The guiding principles are to divert fistula output away from the wound, protect periwound skin, and maintain negative pressure when possible. Techniques include wound manager or fistula pouching systems using custom-cut ostomy appliances applied around the fistula opening to allow output measurement. Negative pressure wound therapy with fistula isolation uses a VAC dressing applied to the wound with the fistula opening isolated using a "fistula plug" or baby nipple directed into a separate collection system. The enterostomal therapy (ET) nurse is an essential team member with expertise in wound management and pouching techniques. Skin barrier products including zinc oxide, cyanoacrylate skin protectants, hydrocolloid wafers, and stoma powder protect the periwound skin.
Nutritional Support
Malnutrition is nearly universal in ECF patients and is the primary driver of morbidity and mortality. Nutritional assessment uses albumin, prealbumin (which has a half-life of 2 to 3 days making it more reflective of acute status), weight trends, and body composition.
Enteral nutrition is preferred when feasible. Distal feeding through a distal limb of bowel via a distal mucous fistula or feeding tube beyond the fistula is ideal when accessible. Fistuloclysis involves reinfusing proximal fistula output into the distal bowel limb; while labor-intensive, it restores enteral nutrition and reduces TPN dependence. Total parenteral nutrition (TPN) is required when enteral access is insufficient, targeting 25 to 30 kcal/kg/day and 1.5 to 2 g protein/kg/day while monitoring for hepatic steatosis, line sepsis, and metabolic complications. Micronutrient supplementation with zinc, selenium, vitamins A, C, and D, iron, and B12 is particularly important with proximal fistulae.
<image>Infographic of the SNAP protocol for enterocutaneous fistula management showing the four sequential phases: Sepsis control (CT-guided drainage, antibiotics, wound management), Nutrition (TPN, enteral feeding, fistuloclysis), Anatomy delineation (CT, fistulogram, MRI), and Procedure planning (timing 6-12 months, surgical approach, goals), with key interventions and milestones at each phase</image>
Anatomic Delineation
Anatomic delineation is performed after sepsis is controlled and the patient is nutritionally optimized. CT abdomen and pelvis with oral and IV contrast identifies abscesses, bowel anatomy, mesh position, abdominal wall defects, and fistula tracts. Fistulogram, performed by injecting water-soluble contrast through the fistula opening under fluoroscopy, delineates tract anatomy, distal bowel continuity, and associated abscess cavities. MRI provides superior soft tissue detail and is useful for complex perineal fistulae in Crohn's disease. Upper GI series and small bowel follow-through assess bowel length and transit. The key questions to answer are the location and number of fistulae, the length of remaining functional bowel, the presence of distal obstruction, and the condition of the abdominal wall.
Spontaneous Closure
Approximately 20 to 30% of ECFs will close spontaneously with conservative management. Favorable factors include low output, long tract, no distal obstruction, no epithelialization, no underlying disease such as Crohn's, cancer, or radiation, and nutritional optimization. Most spontaneous closures occur within 4 to 6 weeks of adequate nutrition and sepsis control; if no closure occurs by 6 to 8 weeks, spontaneous closure is unlikely. The FRIENDS mnemonic identifies factors preventing closure: Foreign body, Radiation, Infection/IBD, Epithelialization, Neoplasm, Distal obstruction, and Short tract or high output.
Definitive Surgical Management
Timing
Surgery should be delayed 6 to 12 months from the last abdominal operation to allow adhesions to mature and soften during the so-called "honeymoon period." Premature reoperation in the hostile abdomen carries a high rate of iatrogenic enterotomy and recurrent fistula of 20 to 35%. The patient must be nutritionally optimized with albumin above 3.0 g/dL and prealbumin above 15 mg/dL and must be free of sepsis.
Operative Principles
Complete adhesiolysis begins by entering the abdomen through virgin territory if possible, using sharp dissection with meticulous technique and running the entire bowel from the ligament of Treitz to the rectum. The fistula is managed by resecting the involved segment of bowel rather than oversewing it, since oversewing has a recurrence rate exceeding 30%. Bowel continuity is restored with primary anastomosis if the abdomen is clean and the patient is well-nourished, or with proximal diversion if conditions are unfavorable. Abdominal wall reconstruction is often required simultaneously, using component separation with biologic mesh underlay as the standard approach, since synthetic mesh should be avoided in contaminated fields. In severe cases, bowel restoration and abdominal wall reconstruction may be staged.
Clinical Pearls
Premature reoperation on an enterocutaneous fistula in the acute setting should be avoided because surgery in the hostile abdomen creates more fistulae. The SNAP protocol (Sepsis, Nutrition, Anatomy, Procedure) provides a systematic framework for ECF management. High-output fistulae require meticulous fluid and electrolyte replacement, and proton pump inhibitors and loperamide are effective for output reduction. Nutritional optimization with albumin above 3.0 and adequate protein intake is a prerequisite for definitive surgery. Waiting 6 to 12 months from the last operation allows adhesions to mature before definitive repair.
References
- Martinez JL, Luque-de-Leon E, Mier J, et al. Systematic management of postoperative enterocutaneous fistulas: factors related to outcomes. World J Surg. 2008;32(3):436-443.
- Schecter WP, Hirshberg A, Chang DS, et al. Enteric fistulas: principles of management. J Am Coll Surg. 2009;209(4):484-491.
- Gribovskaja-Rupp I, Melton GB. Enterocutaneous fistula: proven strategies and updates. Clin Colon Rectal Surg. 2016;29(2):130-137.
- Visschers RG, Olde Damink SW, Winkens B, et al. Treatment strategies in 135 consecutive patients with enterocutaneous fistulas. World J Surg. 2008;32(3):445-453.
